; (C) in paragraph (2), by striking HCV infection and all that follows through the period at the end and inserting infections as a result of injection drug use, receiving blood transfusions prior to July 1992, or other risk factors. ; (D) in paragraphs (4) and (5), by striking HCV infection each place such term appears and inserting infections described in paragraph (1) ; and (E) in paragraph (5), by striking pediatricians and other primary care physicians, and obstetricians and gynecologists and inserting substance use disorder treatment providers, pediatricians, other primary care providers, and obstetrician-gynecologists ; (3) in subsection (b)— (A) by striking directly and and inserting directly or ; and (B) by striking hepatitis C, and all that follows through the period at the end and inserting infections described in subsection (a)(1). ; (4) by redesignating subsection (c) as subsection (d); (5) by inserting after subsection (b) the following: (c) Definition In this section, the term injection drug use means— (1) intravenous administration of a substance in schedule I of section 202(c) of the Controlled Substances Act; (2) intravenous administration of a substance in schedule II, III, IV, or V of section 202(c) of the Controlled Substances Act that has not been approved for intravenous use under section 505 of the Federal Food, Drug and Cosmetic Act or section 351 of the Public Health Service Act; or (3) intravenous administration of a substance in schedule II, III, IV, or V of section 202(c) of the Controlled Substances Act that has not been prescribed to the person using the substance.